A study has shown that trastuzumab emtansine (T-DM1) can specifically bind to exosomes derived from HER2-positive cells, while some studies have explored the potential of exosomes as HER2-positive tumor vaccines by targeting and activating CD4 + and CD8 + T cells, and promoting long-term immune response through CTL memory cells (153, 154). Here, ERBB2 is linked to neoplasm.